A Decensi

Summary

Affiliation: Galliera Hospital
Country: Italy

Publications

  1. doi request reprint Bone mineral density and circulating biomarkers in the BIG 1-98 trial comparing adjuvant letrozole, tamoxifen and their sequences
    Andrea Decensi
    Division of Medical Oncology, E O Ospedali Galliera, Mura delle Cappuccine 14, 16128, Genoa, Italy
    Breast Cancer Res Treat 144:321-9. 2014
  2. doi request reprint A randomized, placebo-controlled, preoperative trial of allopurinol in subjects with colorectal adenoma
    Matteo Puntoni
    Office of the Scientific Director, E O Ospedali Galliera, Genova, Italy
    Cancer Prev Res (Phila) 6:74-81. 2013
  3. pmc A case series of low dose bevacizumab and chemotherapy in heavily pretreated patients with epithelial ovarian cancer
    Carlotta Defferrari
    Unit of Medical Oncology, E, O, Ospedali Galliera, Mura delle Cappuccine 14, 16128, Genoa, Italy
    J Ovarian Res 5:17. 2012
  4. doi request reprint Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial
    Bernardo Bonanni
    Division of Medical Oncology, E O Ospedali Galliera, Mura delle Cappuccine 14, Genoa, Italy
    J Clin Oncol 30:2593-600. 2012
  5. pmc Exemestane for breast cancer prevention: a critical shift?
    Andrea Decensi
    Division of Medical Oncology, Office of the Scientific Director, E O Ospedali Galliera, Genoa, Italy
    Cancer Discov 2:25-40. 2012
  6. doi request reprint Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis
    Andrea Decensi
    Division of Medical Oncology Unit, EO Ospedali Galliera, Mura delle Cappuccine 14, 16128 Genoa, Italy
    Cancer Prev Res (Phila) 3:1451-61. 2010
  7. doi request reprint Lapatinib activity in premalignant lesions and HER-2-positive cancer of the breast in a randomized, placebo-controlled presurgical trial
    Andrea Decensi
    Division of Cancer Prevention and Genetics, European Institute of Oncology, Milan, Italy
    Cancer Prev Res (Phila) 4:1181-9. 2011
  8. doi request reprint Prognostic significance of Ki-67 labeling index after short-term presurgical tamoxifen in women with ER-positive breast cancer
    A Decensi
    Division of Cancer Prevention and Genetics, European Institute of Oncology, Milan, Italy
    Ann Oncol 22:582-7. 2011
  9. pmc Prognostic effect of circulating adiponectin in a randomized 2 x 2 trial of low-dose tamoxifen and fenretinide in premenopausal women at risk for breast cancer
    Debora Macis
    Medical Oncology Unit, E O Ospedali Galliera, Mura delle Cappuccine 14, 16128 Genoa, Italy
    J Clin Oncol 30:151-7. 2012
  10. ncbi request reprint Fenretinide and risk reduction of second breast cancer
    Andrea Decensi
    E O Ospedali Galliera, Division of Medical Oncology, Via Volta 6, Genoa 16128, Italy
    Nat Clin Pract Oncol 4:64-5. 2007

Detail Information

Publications82

  1. doi request reprint Bone mineral density and circulating biomarkers in the BIG 1-98 trial comparing adjuvant letrozole, tamoxifen and their sequences
    Andrea Decensi
    Division of Medical Oncology, E O Ospedali Galliera, Mura delle Cappuccine 14, 16128, Genoa, Italy
    Breast Cancer Res Treat 144:321-9. 2014
    ..C-telopeptide and osteocalcin are useful markers of bone density that may be used to monitor bone health during treatment. The sequence LT may be a valid treatment option in patients with low and intermediate risk of recurrence. ..
  2. doi request reprint A randomized, placebo-controlled, preoperative trial of allopurinol in subjects with colorectal adenoma
    Matteo Puntoni
    Office of the Scientific Director, E O Ospedali Galliera, Genova, Italy
    Cancer Prev Res (Phila) 6:74-81. 2013
    ..Allopurinol can inhibit biomarkers of oxidative activation in colon adenomatous polyps and normal adjacent tissue. Further studies should define its potential chemopreventive activity...
  3. pmc A case series of low dose bevacizumab and chemotherapy in heavily pretreated patients with epithelial ovarian cancer
    Carlotta Defferrari
    Unit of Medical Oncology, E, O, Ospedali Galliera, Mura delle Cappuccine 14, 16128, Genoa, Italy
    J Ovarian Res 5:17. 2012
    ..abstract:..
  4. doi request reprint Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial
    Bernardo Bonanni
    Division of Medical Oncology, E O Ospedali Galliera, Mura delle Cappuccine 14, Genoa, Italy
    J Clin Oncol 30:2593-600. 2012
    ..The change in Ki-67 between pretreatment biopsy and post-treatment surgical specimen has prognostic value and may predict antitumor activity in breast cancer...
  5. pmc Exemestane for breast cancer prevention: a critical shift?
    Andrea Decensi
    Division of Medical Oncology, Office of the Scientific Director, E O Ospedali Galliera, Genoa, Italy
    Cancer Discov 2:25-40. 2012
    ..Additional issues for prevention, including the influence of obesity, alternative dosing, and biomarker use in phase III trials, are addressed...
  6. doi request reprint Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis
    Andrea Decensi
    Division of Medical Oncology Unit, EO Ospedali Galliera, Mura delle Cappuccine 14, 16128 Genoa, Italy
    Cancer Prev Res (Phila) 3:1451-61. 2010
    ..Given the retrospective nature of most studies and the possibility that the control treatments increase risk, phase II trials are needed before large cancer prevention trials are launched...
  7. doi request reprint Lapatinib activity in premalignant lesions and HER-2-positive cancer of the breast in a randomized, placebo-controlled presurgical trial
    Andrea Decensi
    Division of Cancer Prevention and Genetics, European Institute of Oncology, Milan, Italy
    Cancer Prev Res (Phila) 4:1181-9. 2011
    ....
  8. doi request reprint Prognostic significance of Ki-67 labeling index after short-term presurgical tamoxifen in women with ER-positive breast cancer
    A Decensi
    Division of Cancer Prevention and Genetics, European Institute of Oncology, Milan, Italy
    Ann Oncol 22:582-7. 2011
    ..Studies have shown that Ki-67 response after short-term neoadjuvant aromatase inhibitors may predict recurrence in postmenopausal breast cancer, whereas its prognostic effect in premenopausal women is unknown...
  9. pmc Prognostic effect of circulating adiponectin in a randomized 2 x 2 trial of low-dose tamoxifen and fenretinide in premenopausal women at risk for breast cancer
    Debora Macis
    Medical Oncology Unit, E O Ospedali Galliera, Mura delle Cappuccine 14, 16128 Genoa, Italy
    J Clin Oncol 30:151-7. 2012
    ..We investigated the associations of plasma leptin and adiponectin with mammographic density and disease status and assessed their prognostic effect on recurrence-free survival in premenopausal women at risk for breast cancer...
  10. ncbi request reprint Fenretinide and risk reduction of second breast cancer
    Andrea Decensi
    E O Ospedali Galliera, Division of Medical Oncology, Via Volta 6, Genoa 16128, Italy
    Nat Clin Pract Oncol 4:64-5. 2007
  11. pmc Randomized double-blind 2 x 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in high-risk premenopausal women
    Andrea Decensi
    Division of Medical Oncology, EO Ospedali Galliera, Mura delle Cappuccine 14, 16128 Genoa, Italy
    J Clin Oncol 27:3749-56. 2009
    ..Tamoxifen and fenretinide are active in reducing premenopausal breast cancer risk and work synergistically in preclinical models. The authors assessed their combination in a two-by-two biomarker trial...
  12. ncbi request reprint Randomized dose-ranging trial of tamoxifen at low doses in hormone replacement therapy users
    Andrea Decensi
    Division of Chemoprevention, European Institute of Oncology, Milan, Italy
    J Clin Oncol 25:4201-9. 2007
    ..We assessed the optimal biologic dose and schedule of tamoxifen in HRT users using surrogate end point biomarkers and menopausal symptoms...
  13. ncbi request reprint Chemoprevention of breast cancer: the Italian experience
    A Decensi
    Chemoprevention Unit, European Institute of Oncology, Milan, Italy
    J Cell Biochem Suppl 34:84-96. 2000
    ..Moreover, updated results of the secondary prevention trial of 4-H PR and of the primary prevention trial of tamoxifen are presented. Finally, the rationale for a reduction of tamoxifen dose in future prevention trials is provided...
  14. ncbi request reprint Biologic activity of tamoxifen at low doses in healthy women
    A Decensi
    Chemoprevention Unit, European Institute of Oncology, Milan, Italy
    J Natl Cancer Inst 90:1461-7. 1998
    ..Since these adverse effects may be dose related, we investigated the effect of tamoxifen on several biomarkers when the drug was given at doses lower than those currently in use...
  15. ncbi request reprint Effect of low dose tamoxifen on the insulin-like growth factor system in healthy women
    B Bonanni
    Division of Chemoprevention, European Institute of Oncology, Milan, Italy
    Breast Cancer Res Treat 69:21-7. 2001
    ..Further studies on the search of the minimal active dose of tamoxifen are warranted...
  16. ncbi request reprint Effect of tamoxifen on lipoprotein(a) and insulin-like growth factor-I (IGF-I) in healthy women
    A Decensi
    FIRC Chemoprevention Unit, European Institute of Oncology, Milan, Italy
    Eur J Cancer 35:596-600. 1999
    ..Our results support the observation that tamoxifen may be a suitable preventive option for women with multiple disease risk factors...
  17. ncbi request reprint Effect of blood tamoxifen concentrations on surrogate biomarkers in a trial of dose reduction in healthy women
    A Decensi
    Chemoprevention Unit, the Division of Epidemiology and Biostatistics, and the Division of Laboratory Medicine, European Institute of Oncology, Milan, Italy
    J Clin Oncol 17:2633-8. 1999
    ..Because toxicity may be dose-dependent, we studied the biologic activity of low concentrations of tamoxifen to determine the plausibility of a dose reduction...
  18. pmc Effect of tamoxifen and transdermal hormone replacement therapy on cardiovascular risk factors in a prevention trial. Italian Chemoprevention Group
    A Decensi
    FIRC Chemoprovention Unit, European Institute of Oncology, Milan, Italy
    Br J Cancer 78:572-8. 1998
    ..Whereas a trial of tamoxifen in women already on transdermal HRT is warranted, prescription of HRT during tamoxifen may attenuate its activity...
  19. pmc Tailoring treatment for ductal intraepithelial neoplasia of the breast according to Ki-67 and molecular phenotype
    M Lazzeroni
    Division of Cancer Prevention and Genetics, European Institute of Oncology, Milan, Italy
    Br J Cancer 108:1593-601. 2013
    ..The post-surgical management of ductal intraepithelial neoplasia (DIN) of the breast is still a dilemma. Ki-67 labelling index (LI) has been proposed as an independent predictive and prognostic factor in early breast cancer...
  20. ncbi request reprint Long-term effects of fenretinide, a retinoic acid derivative, on the insulin-like growth factor system in women with early breast cancer
    A Decensi
    Division of Chemoprevention, European Institute of Oncology, 20141 Milan, Italy
    Cancer Epidemiol Biomarkers Prev 10:1047-53. 2001
    ..Fenretinide induces a moderate decline of IGF-I levels in women < or = 50 years of age. The association between IGF-I change and the reduction of second breast cancers in premenopausal women warrants further study...
  21. doi request reprint Low-dose tamoxifen in the treatment of breast ductal intraepithelial neoplasia: results of a large observational study
    A Guerrieri-Gonzaga
    Division of Cancer Prevention and Genetics, European Institute of Oncology, Milan, Italy
    Ann Oncol 21:949-54. 2010
    ..Since low-dose tamoxifen showed a favorable modulation of breast cancer biomarkers in phase II trials, a monoinstitutional cohort of women with DIN treated with low-dose tamoxifen or no systemic treatment was analyzed...
  22. pmc The effect of metformin on apoptosis in a breast cancer presurgical trial
    M Cazzaniga
    Division of Cancer Prevention and Genetics, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Br J Cancer 109:2792-7. 2013
    ..We determined whether metformin induced a modulation of apoptosis by terminal deoxynucleotidyl transferase dUTP nick end labelling (TUNEL) overall and by insulin resistance status in a presurgical trial...
  23. ncbi request reprint Safety of the synthetic retinoid fenretinide: long-term results from a controlled clinical trial for the prevention of contralateral breast cancer
    T Camerini
    Istituto Nazionale Tumori, Milan, Italy
    J Clin Oncol 19:1664-70. 2001
    ..CONCLUSION: Given the number of patients involved in the study and the prolonged intake of the drug, the experience on fenretinide tolerability can be considered sufficiently reassuring to justify further testing of the retinoid...
  24. ncbi request reprint Correlation between tamoxifen elimination and biomarker recovery in a primary prevention trial
    A Guerrieri-Gonzaga
    Division of Chemoprevention, European Institute of Oncology, 20141 Milan, Italy
    Cancer Epidemiol Biomarkers Prev 10:967-70. 2001
    ..In addition, the prolonged half-life of tamoxifen and metabolite provides the rationale for a weekly administration of the drug in a preventive context. However, the clinical implications of our findings remain to be defined...
  25. pmc Tamoxifen reduces plasma homocysteine levels in healthy women
    M Cattaneo
    Angelo Bianchi Bonomi Haemophilia and Thrombosis Centre, IRCCS Ospedale Maggiore, Institute of Internal Medicine, University of Milano, Milan, Italy
    Br J Cancer 77:2264-6. 1998
    ..In conclusion, tamoxifen (20 mg day(-1) for 6 months) decreased plasma tHcy levels in healthy women. This effect may contribute to its protective effect on myocardial infarction...
  26. doi request reprint Effect of low-dose tamoxifen after surgical excision of ductal intraepithelial neoplasia: results of a large retrospective monoinstitutional cohort study
    A Guerrieri-Gonzaga
    Division of Medical Oncology, E O Ospedali Galliera, Mura delle Cappuccine 14, 16128 Genoa, Italy
    Ann Oncol 24:1859-66. 2013
    ..Given positive results of low-dose tamoxifen on breast cancer biomarkers modulation, we analyzed a large cohort of DIN patients treated with low-dose tamoxifen or no treatment as per institutional guidelines...
  27. pmc Effect of raloxifene on IGF-I and IGFBP-3 in postmenopausal women with breast cancer
    R Torrisi
    Division of Chemoprevention, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Br J Cancer 85:1838-41. 2001
    ..Given that high plasma levels of IGF-I have been suggested as a risk factor for breast cancer, these findings provide further support for the potential activity of raloxifene in breast cancer prevention...
  28. ncbi request reprint Randomized trial of fenretinide in superficial bladder cancer using DNA flow cytometry as an intermediate end point
    A Decensi
    Division of Medical Oncology II, National Cancer Institute, Genoa, Italy
    Cancer Epidemiol Biomarkers Prev 9:1071-8. 2000
    ..Because our data are hampered by the lack of predictivity of the selected biomarkers, additional studies are necessary to assess the activity of fenretinide in preventing bladder cancer...
  29. ncbi request reprint Recent advances in cancer chemoprevention, with emphasis on breast and colorectal cancer
    A Decensi
    Chemoprevention Unit, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy
    Eur J Cancer 36:694-709. 2000
    ..Current knowledge suggests that a pharmacological approach to preventing cancer, using natural or synthetic agents, could become an important way forward...
  30. ncbi request reprint Effect of tamoxifen at low doses on ultrasensitive C-reactive protein in healthy women
    B Bonanni
    Division of Chemoprevention, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    J Thromb Haemost 1:2149-52. 2003
    ..5-36.3) for women with low tamoxifen concentrations (< 30 ng mL-1). We conclude that tamoxifen at low doses is able to lower ultrasensitive CRP and that this might be associated with a beneficial effect on CVD...
  31. doi request reprint A phase-III prevention trial of low-dose tamoxifen in postmenopausal hormone replacement therapy users: the HOT study
    A Decensi
    Division of Medical Oncology, Ospedali Galliera, Genova Divisions of
    Ann Oncol 24:2753-60. 2013
    ..Postmenopausal hormone replacement therapy (HRT) relieves menopausal symptoms and may decrease mortality in recently postmenopausal women, but increases breast cancer risk. Low-dose tamoxifen has shown retained activity in phase-II studies...
  32. ncbi request reprint Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer
    U Veronesi
    European Institute of Oncology, Milan, Italy
    Ann Oncol 17:1065-71. 2006
    ..We conducted a long-term analysis in a subgroup of women who were regularly followed up in a single center...
  33. ncbi request reprint The Italian breast cancer prevention trial with tamoxifen: findings and new perspectives
    A Guerrieri-Gonzaga
    Division of Chemoprevention, European Institute of Oncology, Milan, Italy
    Ann N Y Acad Sci 949:113-22. 2001
    ....
  34. pmc The effect of transdermal estradiol or oral conjugated oestrogen and fenretinide versus placebo on haemostasis and cardiovascular risk biomarkers in a randomized breast cancer chemoprevention trial
    M Lazzeroni
    Cancer Prevention and Genetics, European Institute of Oncology, 20141 Milan, Italy
    Ecancermedicalscience 2:67. 2008
    ..Here, we investigate the changes in lipids and clotting profile in patients of the same trial...
  35. ncbi request reprint Preliminary results on safety and activity of a randomized, double-blind, 2 x 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in premenopausal women
    Aliana Guerrieri-Gonzaga
    Division of Chemoprevention, European Institute of Oncology, Milan, Italy
    J Clin Oncol 24:129-35. 2006
    ....
  36. ncbi request reprint Estramustine phosphate (estracyt) following androgens in men with refractory stage D2 prostate cancer
    F Boccardo
    Department of Clinical Oncology, National Cancer Institute, Genova, Italy
    Cancer Chemother Pharmacol 22:172-4. 1988
    ..In this group of patients, androgen priming did not seem to potentiate the effectiveness of EMP, our results being comparable to those previously reported using EMP alone...
  37. pmc Modulation of the insulin-like growth factor-I system by N-(4-hydroxyphenyl)-retinamide in human breast cancer cell lines
    R E Favoni
    Department of Preclinical Oncology, National Institute for Cancer Research and Advanced Biotechnology Center, Genoa, Italy
    Br J Cancer 77:2138-47. 1998
    ..These findings suggest that, in our model, interference with the ER signalling pathway is not the only mechanism of breast cancer growth inhibition by 4-HPR...
  38. ncbi request reprint Effect of fenretinide on bone mineral density and metabolism in women with early breast cancer
    A Decensi
    Department of Medical Oncology II, European Institute of Oncology, Milan, Italy
    Breast Cancer Res Treat 53:145-51. 1999
    ..However, a trend towards an increase in bone resorption markers suggests the need for further assessment at different skeletal sites...
  39. doi request reprint Efficacy of tamoxifen based on cytochrome P450 2D6, CYP2C19 and SULT1A1 genotype in the Italian Tamoxifen Prevention Trial
    D Serrano
    Division of Cancer Prevention and Genetics, European Institute of Oncology, Milan, Italy
    Pharmacogenomics J 11:100-7. 2011
    ..Conversely, the CYP2D6*2A allele may be associated with increased efficacy of tamoxifen. These findings support the relevance of pharmaco-genomics in tailoring tamoxifen treatment...
  40. ncbi request reprint Chemoprevention of breast cancer with fenretinide
    R Torrisi
    Chemoprevention Unit, European Institute of Oncology, Milan, Italy
    Drugs 61:909-18. 2001
    ....
  41. ncbi request reprint Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women
    Umberto Veronesi
    European Institute of Oncology, Milan, Italy
    J Natl Cancer Inst 95:160-5. 2003
    ..Such a strategy would greatly reduce the numbers of women who would need to take tamoxifen to obtain the same absolute reduction in breast cancer. These findings are exploratory and need to be confirmed in other randomized trials...
  42. ncbi request reprint Relationships between plasma insulin-like growth factor-I and insulin-like growth factor binding protein-3 and second breast cancer risk in a prevention trial of fenretinide
    Andrea Decensi
    Division of Chemoprevention, European Institute of Oncology, Milan 20141, Italy
    Clin Cancer Res 9:4722-9. 2003
    ..We determined whether IGF-I and IGFBP-3 predict second breast cancer risk, and whether their changes during fenretinide explain observed reductions in second breast cancer in women </=50 years of age...
  43. ncbi request reprint A two-by-two factorial trial comparing oral with transdermal estrogen therapy and fenretinide with placebo on breast cancer biomarkers
    Andrea Decensi
    Divisions of Chemoprevention, Epidemiology and Biostatistics, Laboratory Medicine, Radiology, and Gynecology, European Institute of Oncology, Milan, Italy
    Clin Cancer Res 10:4389-97. 2004
    ....
  44. doi request reprint N-(4-hydroxyphenyl)retinamide promotes apoptosis of resting and proliferating B-cell chronic lymphocytic leukemia cells and potentiates fludarabine and ABT-737 cytotoxicity
    S Bruno
    Department of Experimental Medicine DIMES, University of Genoa, Genoa, Italy
    Leukemia 26:2260-8. 2012
    ..Synergic cytotoxicity was also demonstrated in combination with fludarabine, in both resting and stimulated CLL samples. This study entitles 4HPR to be assayed as a chemotherapeutic adjuvant for the treatment of CLL...
  45. pmc Effect of fenretinide and low-dose tamoxifen on insulin sensitivity in premenopausal women at high risk for breast cancer
    Harriet Johansson
    Division of Cancer Prevention and Genetics, European Institute of Oncology, University of Milan, Italy
    Cancer Res 68:9512-8. 2008
    ..Furthermore, features of the metabolic syndrome should be taken into consideration before proposing tamoxifen for breast cancer prevention. The clinical implications of these results require further investigations...
  46. ncbi request reprint Clinical trials with retinoids for breast cancer chemoprevention
    S Zanardi
    Department of Medical and Preventive Oncology, E O Ospedali Galliera, Mura delle Cappuccine 14, 16128 Genoa, Italy
    Endocr Relat Cancer 13:51-68. 2006
    ..The rexinoid, bexarotene, has recently been approved for the treatment of patients with cutaneous T-cell lymphoma, and a biomarker trial with bexarotene in women with high breast cancer risk is currently underway...
  47. ncbi request reprint Rationale for a study adding tamoxifen to HRT
    N Rotmensz
    European Institute of Oncology, Milan, Italy
    Eur J Cancer 38:S22-3. 2002
  48. ncbi request reprint Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy
    Umberto Veronesi
    Scientific Directorate, European Institute of Oncology, Milan, Italy
    J Natl Cancer Inst 99:727-37. 2007
    ..Here we present an extended follow-up of the Italian trial...
  49. ncbi request reprint Effect of tamoxifen on venous thromboembolic events in a breast cancer prevention trial
    Andrea Decensi
    Divisions of Chemoprevention, European Institute of Oncology, Milan, Italy
    Circulation 111:650-6. 2005
    ..Atherosclerosis may induce VTE, or the 2 conditions may share common risk factors. We assessed the effect of tamoxifen on VTE in a breast cancer prevention trial and studied its association with risk factors for VTE...
  50. ncbi request reprint SERMs in chemoprevention of breast cancer
    Milena Gasco
    Division of Medical and Preventive Oncology, E O Ospedali Galliera, 16128 Genoa, Italy
    Eur J Cancer 41:1980-9. 2005
    ..Finally, new agents that interfere with the onset of ER-negative breast cancer are being sought for combination chemoprevention since almost a third of breast cancers will not be sensitive to hormonal modulation...
  51. ncbi request reprint A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers
    Andrea Decensi
    Division of Chemoprevention, European Institute of Oncology, and University of Milan School of Medicine, Milan, Italy
    J Natl Cancer Inst 95:779-90. 2003
    ....
  52. ncbi request reprint Progress in chemoprevention of breast cancer
    Davide Serrano
    Division of Chemoprevention, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Crit Rev Oncol Hematol 49:109-17. 2004
    ..Finally, new targets that interfere with ER-negative breast carcinogenesis are being sought as one-third of breast cancers will not be preventable by hormonal interventions...
  53. doi request reprint Inflammation and cancer prevention
    M Puntoni
    Medical Oncology Unit, Galliera Hospital, Genoa, Italy
    Ann Oncol 19:vii225-9. 2008
  54. ncbi request reprint Effect of fenretinide on ovarian carcinoma occurrence
    Giuseppe De Palo
    Unit of Preventive Medicine and Cancer Family Clinic, Istituto Nazionale Tumori, Milan, Italy
    Gynecol Oncol 86:24-7. 2002
    ..The aim of this study was to update the effect of fenretinide, a synthetic vitamin A analogue proposed for chemoprevention, on the occurrence of ovarian carcinoma...
  55. doi request reprint Randomized biomarker trial of anastrozole or low-dose tamoxifen or their combination in subjects with breast intraepithelial neoplasia
    Bernardo Bonanni
    Divisions of Cancer Prevention and Genetics, European Institute of Oncology, Milan, University of Milan School of Medicine, Milan, Italy
    Clin Cancer Res 15:7053-60. 2009
    ..The influence of CYP2D6 genotype on tamoxifen effects was also determined...
  56. ncbi request reprint Pharmacological prevention of breast cancer: quo vadis?
    Davide Serrano
    Division of Chemoprevention, European Institute of Oncology, Milan, Italy
    Breast 12:379-86. 2003
    ..Finally, new targets that interfere with the onset of ER-negative breast cancer are being sought since one-third of breast cancers will not be modulated by hormonal interventions...
  57. ncbi request reprint Relationships between circulating hormone levels, mammographic percent density and breast cancer risk factors in postmenopausal women
    Harriet Johansson
    Division of Cancer Prevention and Genetics, European Institute of Oncology, Milan, Italy
    Breast Cancer Res Treat 108:57-67. 2008
    ..The aim of this study was to assess the relationships between circulating hormones, clinical features related to breast cancer risk and mammographic density in postmenopausal women...
  58. ncbi request reprint A phase I-II preoperative biomarker trial of fenretinide in ascitic ovarian cancer
    Nicoletta Colombo
    Division of Gynecologic Oncology, European Institute of Oncology, Milan, Italy
    Cancer Epidemiol Biomarkers Prev 15:1914-9. 2006
    ....
  59. pmc Stimulation of erythropoiesis by the non-steroidal anti-androgen nilutamide in men with prostate cancer: evidence for an agonistic effect?
    A Decensi
    Department of Medical Oncology II, National Institute for Cancer Research, Genoa, Italy
    Br J Cancer 69:617-9. 1994
    ..Ongoing randomised trials should address this issue...
  60. ncbi request reprint Factors associated with circulating levels of insulin-like growth factor-I and insulin-like growth factor binding protein-3 in 740 women at risk for breast cancer
    Harriet Johansson
    Division of Chemoprevention, European Institute of Oncology, Milan, Italy
    Breast Cancer Res Treat 88:63-73. 2004
    ..These findings support their putative role as breast cancer risk biomarker...
  61. ncbi request reprint Breast cancer prevention trials using retinoids
    Andrea Decensi
    Division of Chemoprevention, European Institute of Oncology, Milan, Italy
    J Mammary Gland Biol Neoplasia 8:19-30. 2003
    ....
  62. ncbi request reprint Effects of raloxifene on sex steroid hormones and C-telopeptide in postmenopausal women with primary breast cancer
    Harriet Johansson
    Division of Chemoprevention, European Institute of Oncology, Milan, Italy
    Breast Cancer Res Treat 98:167-72. 2006
    ..024) and E2 (p=0.01), and positively with DHEA-S (p=0.016) and CTX (p=0.040). Our results provide evidence for an early endocrine effect of raloxifene which further suggests a favorable impact on breast cancer prevention...
  63. ncbi request reprint HRT opposed to low-dose tamoxifen (HOT study): rationale and design
    Andrea Decensi
    European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Recent Results Cancer Res 163:104-11; discussion 264-6. 2003
    ....
  64. ncbi request reprint Methylenetetrahydrofolate reductase (MTHFR) and breast cancer risk: a nested-case-control study and a pooled meta-analysis
    Debora Macis
    Division of Chemoprevention, European Institute of Oncology, Milan, Italy
    Breast Cancer Res Treat 106:263-71. 2007
    ..A reduced activity of methylenetetrahydrofolate reductase (MTHFR) due to frequent C677T polymorphism affects DNA synthesis, repair and methylation and may be implicated in breast cancer risk...
  65. ncbi request reprint Effect of transdermal estradiol and oral conjugated estrogen on C-reactive protein in retinoid-placebo trial in healthy women
    Andrea Decensi
    Division of Chemoprevention, European Institute of Oncology, Milan, Italy
    Circulation 106:1224-8. 2002
    ..Because the effect of transdermal estradiol (E2) on CRP is unclear, we compared CRP changes after 6 and 12 months of transdermal E2 and oral CEE in a randomized 2x2 retinoid-placebo trial...
  66. ncbi request reprint Prognostic effect of DNA aneuploidy from bladder washings in superficial bladder cancer
    Matteo Puntoni
    Division of Medical Oncology, E O Ospedali Galliera, Mura delle Cappuccine 14, 16128 Genoa, Italy
    Cancer Epidemiol Biomarkers Prev 16:979-83. 2007
    ..Superficial (papillary) bladder cancer is associated with progression and death from muscle-invasive bladder cancer, but no reliable predictors of the outcomes have been identified...
  67. ncbi request reprint Phase II study with lonidamine in the treatment of hormone-refractory prostatic cancer patients
    F Boccardo
    Servizio di Oncologia Medica II, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy
    Tumori 78:137-9. 1992
    ..We conclude that this therapeutic approach with lonidamine is not active in hormone-refractory prostatic cancer patients with distant metastasis...
  68. ncbi request reprint Chemoprevention of colorectal cancer: an update
    D Serrano
    Division of Chemoprevention, European Institute of Oncology, Via Ripamonti 435, I 20141 Milan, Italy
    Tech Coloproctol 8:s248-52. 2004
    ..In conclusion, the rapid growth of information and knowledge in chemoprevention, especially for CRC, is very encouraging and gives us hope that soon this approach will be applicable in a larger scale population...
  69. ncbi request reprint Biomarkers for risk assessment and prevention of breast cancer
    Massimiliano Cazzaniga
    Division of Cancer Prevention and Genetics, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy
    Curr Cancer Drug Targets 9:482-99. 2009
    ....
  70. doi request reprint Is it time to test metformin in breast cancer clinical trials?
    Massimiliano Cazzaniga
    Division of Cancer Prevention and Genetics, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy
    Cancer Epidemiol Biomarkers Prev 18:701-5. 2009
    ..The confirmation of the efficacy of metformin on cancer cell proliferation may lead the way to larger chemoprevention clinical trials...
  71. ncbi request reprint Quality of life assessment in a chemoprevention trial: fenretinide and oral or transdermal HRT
    Davide Serrano
    Division of Chemoprevention, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Maturitas 55:69-75. 2006
    ..We have evaluated the quality of life through a self-administered questionnaire during a randomized study of oral CEE or transdermal E2 and fenretinide or placebo...
  72. doi request reprint Ductal intraepithelial neoplasia: postsurgical outcome for 1,267 women cared for in one single institution over 10 years
    Aliana Guerrieri-Gonzaga
    Division of Cancer Prevention and Genetics, European Institute of Oncology, Milan, Italy
    Oncologist 14:201-12. 2009
    ..We analyzed risk factors and treatment outcome in a large series of women treated at one institution...
  73. doi request reprint Analysis of the presence of cutaneous and mucosal papillomavirus types in ductal lavage fluid, milk and colostrum to evaluate its role in breast carcinogenesis
    Massimiliano Cazzaniga
    Division of Chemoprevention, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Breast Cancer Res Treat 114:599-605. 2009
    ..Our data show that DNA of alpha mucosa and beta cutaneous HPV types are rarely present in the breast fluids and suggest that a direct role of HPV in breast carcinogenesis is unlikely...
  74. ncbi request reprint Computer-assisted image analysis of breast fine needle aspiration in a randomized chemoprevention trial of fenretinide vs. placebo in HRT users
    Davide Serrano
    Division of Chemoprevention, European Institute of Oncology, Milan, Italy
    Breast 17:91-7. 2008
    ..Digital nuclear morphometric analysis can capture subtle differences along neoplastic progression. Studies showed different profiles from normal to cancer lesions. Our goal is to utilize this method as biomarker in chemoprevention trials...
  75. ncbi request reprint Atypia and Ki-67 expression from ductal lavage in women at different risk for breast cancer
    Massimiliano Cazzaniga
    Division of Chemoprevention, European Institute of Oncology, Milan, Italy
    Cancer Epidemiol Biomarkers Prev 15:1311-5. 2006
    ..We studied the prevalence and predictors of atypia in addition to the proliferation-associated antigen Ki-67 expression in ductal lavage done in women at different risk of breast cancer...
  76. doi request reprint Psychological and clinical factors implicated in decision making about a trial of low-dose tamoxifen in hormone replacement therapy users
    Gabriella Rondanina
    Medical Oncology Unit, Galliera Hospital, Genoa, Italy
    J Clin Oncol 26:1537-43. 2008
    ..To assess the sociodemographic, health-related, and psychological factors that influence the decision of women on hormone replacement therapy (HRT) to participate in a phase III trial of low-dose tamoxifen...
  77. ncbi request reprint Tamoxifen: an enduring star
    Umberto Veronesi
    J Natl Cancer Inst 99:258-60. 2007
  78. pmc Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial
    Savino Bruno
    Liver Unit, Azienda Ospedaliera Fatebenefratelli e Oftalmico, Corso di Porta Nuova 23, 20121 Milan, Italy
    BMJ 330:932. 2005
    ..To assess the incidence, cofactors, and excess risk of development of non-alcoholic fatty liver disease, including non-alcoholic steatohepatitis, attributable to tamoxifen in women...
  79. ncbi request reprint Effect of the synthetic retinoid fenretinide on circulating free prostate-specific antigen, insulin-like growth factor-I, and insulin-like growth factor binding protein-3 levels in men with superficial bladder cancer
    Davide Serrano
    Division of Chemoprevention, Cancer Epidemiology Center, Cancer Council of Victoria, Melbourne, Australia
    Clin Cancer Res 11:2083-8. 2005
    ..Fenretinide (4-HPR) is a synthetic retinoid that has shown a preventive activity in prostate cancer animal models...
  80. ncbi request reprint [Risks and benefits of hormone replacement therapy: clinical considerations and research implications]
    Andrea Decensi
    Divisione di farmacoprevenzione, Istituto Europeo di Oncologia, Milano
    Epidemiol Prev 26:280-2. 2002
  81. ncbi request reprint Tamoxifen and metabolite concentrations in serum and breast cancer tissue during three dose regimens in a randomized preoperative trial
    Elton R Kisanga
    Hormone Laboratory, Haukeland University Hospital, Department of Medicine, and Centre for International Health, University of Bergen, Bergen, Norway
    Clin Cancer Res 10:2336-43. 2004
    ..Furthermore we studied tamoxifen effects on the cancer proliferation marker Ki-67, and on sex hormone-binding globulin (SHBG)...
  82. ncbi request reprint Phase I trial and pharmacokinetics of fenretinide in children with neuroblastoma
    Alberto Garaventa
    Department of Pediatric Hematology Oncology, G Gaslini Children s Hospital, Genova, Italy
    Clin Cancer Res 9:2032-9. 2003
    ..Fenretinide (4HPR), a synthetic retinoid, induces apoptosis in neuroblastoma cells. A Phase I study in children with neuroblastoma was designed to determine maximum tolerated dose, toxicity, and pharmacokinetics...